Your browser doesn't support javascript.
loading
Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo, I; Álvarez-Chinchilla, P; Schneller-Pavelescu, L; Hispán-Ocete, P; Bañuls-Roca, J.
Afiliação
  • Poveda-Montoyo I; Departamento de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain. Electronic address: inespovedamontoyo@gmail.com.
  • Álvarez-Chinchilla P; Departamento de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
  • Schneller-Pavelescu L; Departamento de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
  • Hispán-Ocete P; Departamento de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
  • Bañuls-Roca J; Departamento de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain; Unidad de Dermatología Área, Departamento de Medicina Clínica, Universidad Miguel Hernández, Sant Joan de Alicante, Alicante, Spain.
Actas Dermosifiliogr ; 113(4): 407-412, 2022 Apr.
Article em En, Es | MEDLINE | ID: mdl-35431054
Topical imiquimod has been used off-label as monotherapy or adjuvant treatment for lentigo maligna. Our aim is to describe treatment modalities, clinical outcomes, and management of recurrence in patients receiving imiquimod for lentigo maligna. Patients from our unit with lentigo maligna or lentigo maligna melanoma treated with imiquimod 5% as monotherapy or in combination with surgery were included in this study. Fourteen cases were recruited (85.7% lentigo maligna and 14.3% lentigo maligna melanoma). Eight patients (57.1%) received imiquimod without surgery, and six (42.9%) underwent narrow excision before beginning treatment. During the follow-up period, pigmentation reappeared in 6 patients (4 postinflammatory hyperpigmentation and 2 relapses). Relapses were managed with very narrow excision (1mm margin) and retreatment with imiquimod 5%. All imiquimod modalities showed well-tolerated side effects and low recurrence rates, with long periods of follow-up. Imiquimod appears to be a versatile option for treating LM in suitable candidates.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Sarda Melanótica de Hutchinson Limite: Humans Idioma: En / Es Revista: Actas Dermosifiliogr Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Sarda Melanótica de Hutchinson Limite: Humans Idioma: En / Es Revista: Actas Dermosifiliogr Ano de publicação: 2022 Tipo de documento: Article